Avaliação da bioequivalência entre duas formulações de rivaroxabana ­ 20 mg comprimido revestido ­ administradas em jejum e pós-prandial em voluntários sadios

César, Isabela da Costa; Teixeira, Leonardo de Souza; Duarte, Florência Goltara; Bonetti, Flávia Tinti; Carvalho, Michel; Campos, Daniel Rossi de.
J. bras. econ. saúde (Impr.) ; 14(1)20220400.
Artículo en Portugués | LILACS, ECOS | ID: biblio-1411989

Documentos relacionados

  1. Batch Selection via In Vitro/In Vivo Correlation in Pharmacokinetic Bioequivalence Testing.
  2. Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations.
  3. Development of An HPLC Method for the Determination of Mesalazine in Human Plasma by Fluorimetric Derivatization and Application to A Prototype Pharmacokinetic Study.
  4. Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game".
  5. Bioequivalence Study of Capsules versus Film Tablets Containing Rivaroxaban in Healthy Caucasian Subjects under Fasting and Fed Conditions.
  6. Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug.
  7. Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations.
  8. A new PK equivalence test for a bridging study.
  9. Influence of Different Populations on Pharmacokinetic Bioequivalence Results: Can We Extrapolate Bioequivalence Results from One Population to Another?
  10. Checking distributional assumptions for pharmacokinetic summary statistics based on simulations with compartmental models.